OpenEvidence has reached $12 billion, with a new round led by Thrive, DST

The venture capital firms that backed OpenEvidence appear to be unconcerned about the new health information products from OpenAI and Anthropic.

The startup announced Wednesday that it has raised an additional $250 million in Series D funding at a $12 billion valuation, co-led by Thrive Capital and DST.

That’s double the valuation from the last increase in October: $200 million at a valuation of $6 billion, led by total value. The company says it has now raised a total of $700 million from backers including Sequoia, Nvidia, Kleiner Perkins, Blackstone, Bond, Kraft Ventures, Mayo Clinic and others.

OpenEvidence is an AI-powered medical information platform, similar to the WebMD platform of the previous Internet generation, but geared toward physicians. This puts it somewhat in greater competition with Anthropic’s Claude Healthcare, which is intended for patients, payers and providers, while ChatGPT’s new health product is more aimed at consumers.

The company says the free, ad-supported platform provided 18 million clinical consultations from certified healthcare professionals in the United States in December alone. This compares to about 3 million searches per month a year ago. It also said its revenue exceeded $100 million.